ArticleAnnals of hematology2026
Low dose of sitagliptin: effectively prevent liver aGVHD and accelerate neutrophil engraftment.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
After allogeneic hematopoietic stem cell transplantation (allo-HSCT), the incidence of moderate-to-severe acute graft-versus-host disease (aGVHD) is approximately 13% to 47%. Currently, the standard regimen for the prevention of aGVHD is a calcineurin inhibitor (CNI) plus short-course methotrexate (MTX), with the addition of mycophenolate mofetil (MMF), anti-human thymocyte globulin (ATG), or anti-CD25 monoclonal antibody depending on the type of donor. This study aims to evaluate whether the addition of sitagliptin to standard aGVHD prophylaxis can further reduce the incidence and severity of aGVHD, while enhancing stem cell engraftment and improving the overall prognosis of patients undergoing allo-HSCT. The clinical data of 66 patients with malignant hematopoietic diseases who underwent allogeneic hematopoietic stem cell transplantation for the first time at the Department of Hematology, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology between 1 January 2022 and 1 January 2024 were retrospectively collected. According to the aGVHD prophylaxis regimen received, the patients were divided into the Sitagliptin group (n = 33) and the Standard group (n = 33). Statistical methods were used to compare the clinical outcomes between the two groups, including hematopoietic engraftment, acute GVHD, chronic GVHD, and overall survival (OS) after allogeneic hematopoietic stem cell transplantation. By day + 100 after transplantation, all patients in both groups had achieved engraftment. The Sitagliptin group had faster neutrophil engraftment than the Standard group (median 9 days, 95% CI 8.55–9.45 vs. median 11 days, 95% CI 10.39–11.61; p < 0.001). The cumulative incidence of grade II–IV aGVHD by day + 100 was 39.4% (95% CI 17%–35%) in the Standard group compared with 30.3% in the Sitagliptin group (p = 0.26). Corresponding values for grade III–IV aGVHD were 12.1% (95% CI 3.7%–25.8%) in the Standard group versus 9.1% (95% CI 2.3%–21.9%) in the Sitagliptin group (p = 0.70). For organ-specific aGVHD, the incidence of liver aGVHD was significantly lower in the Sitagliptin group (3.1%, 95% CI 0.2%–14%) than in the Standard group (18.2%, 95% CI 7.2%–33.1%; p = 0.044).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.